Reaction
Anaplastic Large Cell Lymphoma T- And Null-Cell Types reporting signals
As of the last recalculation, Anaplastic Large Cell Lymphoma T- And Null-Cell Types appears in 276 FAERS reports alongside 6 co-occurring drug terms. The strongest observed disproportionality signal is BRENTUXIMAB VEDOTIN (PRR 493.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Brentuximab Vedotin | 54 | 493.7 | 496.3 |
| Dexamethasone Sodium Phosphate | 10 | 77.0 | 77.1 |
| Doxorubicin Hydrochloride | 15 | 36.6 | 36.6 |
| Crizotinib | 6 | 36.4 | 36.4 |
| Doxorubicin | 36 | 34.9 | 34.9 |
| Entecavir | 5 | 32.9 | 32.9 |